Brief: Krystal Biotech Announces Orphan Drug Designation Granted To KB408 For The Treatment Of Alpha-1 Antitrypsin Deficiency
05/09/2023 12:04
Sept 5 (Reuters) - Krystal Biotech Inc KRYS.O :
* KRYSTAL BIOTECH ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED
TO
KB408 FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY
Source text for Eikon: ID:nGNX6HN8Jm
Further company coverage: KRYS.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion